OneSource Specialty Pharma Allots 21,450 Equity Shares Under ESOP 2021

1 min read     Updated on 10 Apr 2026, 08:13 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

OneSource Specialty Pharma Limited allotted 21,450 equity shares under ESOP 2021 on April 09, 2026, at ₹278 per share to eligible employees. This increased the company's paid-up share capital from ₹11,46,21,201 to ₹11,46,42,651. The shares rank pari passu with existing equity shares and comply with SEBI regulations.

powered bylight_fuzz_icon
37334609

*this image is generated using AI for illustrative purposes only.

OneSource Specialty Pharma Limited has announced the allotment of 21,450 equity shares under its Employee Stock Option Plan 2021. The Management Committee of the Board of Directors approved this allotment through a circular resolution on April 09, 2026.

Share Allotment Details

The equity shares were allotted to eligible employees of the company upon exercise of their vested stock options. Each share carries a par value of ₹1 and was issued at an exercise price of ₹278.00 per share, with a premium of ₹277.00 per share.

Parameter: Details
Number of Shares Allotted: 21,450
Exercise Price per Share: ₹278.00
Premium per Share: ₹277.00
Par Value: ₹1
Issue Date: April 09, 2026

Impact on Share Capital

The allotment has resulted in an increase in the company's paid-up share capital. The newly issued shares rank pari passu with the existing equity shares of the company in all respects.

Capital Structure: Before Allotment After Allotment
Paid-up Share Capital: ₹11,46,21,201 ₹11,46,42,651
Total Equity Shares: 11,46,21,201 11,46,42,651

Regulatory Compliance

The allotment was conducted in accordance with the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has informed both BSE Limited and National Stock Exchange of India Limited about this development.

Key Regulatory Details

  • Distinctive Numbers: 125710522 to 125731971
  • Previous SEBI Filing Date: March 12, 2025
  • Lock-in Period: Not applicable
  • Listing Status: Shares are identical to existing shares

The company secretary and compliance officer, Trisha A, signed the regulatory filings on behalf of OneSource Specialty Pharma Limited. The company's registered office is located at Unit No. 902, "Cyber One", Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai 400703.

Historical Stock Returns for Onesource Specialty Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+4.59%+2.45%-5.02%-23.86%-3.16%-15.85%

How might this ESOP exercise impact OneSource Specialty Pharma's employee retention strategy and future talent acquisition in the competitive pharma sector?

What does the ₹278 exercise price suggest about the company's stock performance since the ESOP 2021 plan was initially granted to employees?

Could this employee stock option exercise signal potential upcoming corporate developments or expansion plans that employees are positioning for?

Onesource Specialty Pharma
View Company Insights
View All News
like17
dislike

Onesource Specialty Pharma Maintains FY28 Revenue Target of $400 Million

0 min read     Updated on 07 Apr 2026, 02:02 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Onesource Specialty Pharma has maintained its revenue target of $400 million for FY28, showing confidence in its growth strategy despite ongoing business challenges. The company remains committed to this financial goal while navigating current market conditions in the specialty pharmaceutical sector.

powered bylight_fuzz_icon
37096368

*this image is generated using AI for illustrative purposes only.

Onesource specialty pharma has reaffirmed its commitment to achieving a revenue target of $400 million by FY28, demonstrating the company's confidence in its long-term growth strategy despite current market conditions.

Financial Target Overview

The specialty pharmaceutical company continues to maintain its ambitious revenue projection, signaling management's belief in the underlying strength of its business model and market positioning.

Parameter: Details
Revenue Target: $400 million
Target Timeline: FY28
Business Focus: Specialty pharmaceuticals

Strategic Outlook

Despite acknowledging ongoing business challenges, Onesource Specialty Pharma remains committed to its established financial targets. The company's decision to maintain its FY28 revenue goal of $400 million reflects management's strategic confidence in navigating current market dynamics while pursuing growth opportunities in the specialty pharmaceutical segment.

The pharmaceutical sector continues to present both opportunities and challenges, with companies like Onesource Specialty Pharma focusing on specialized therapeutic areas to drive revenue growth and market expansion.

Historical Stock Returns for Onesource Specialty Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+4.59%+2.45%-5.02%-23.86%-3.16%-15.85%

What specific therapeutic areas or drug pipeline developments will drive Onesource's path to $400 million revenue by FY28?

How might potential regulatory changes in the specialty pharmaceutical sector impact Onesource's aggressive growth timeline?

Will Onesource need to pursue strategic acquisitions or partnerships to achieve this 4x revenue growth target?

Onesource Specialty Pharma
View Company Insights
View All News
like19
dislike

More News on Onesource Specialty Pharma

1 Year Returns:-3.16%